Actively Recruiting
Different Immunosuppressive Treatment in iMN
Led by Peking Union Medical College Hospital · Updated on 2025-12-09
200
Participants Needed
1
Research Sites
450 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
CONDITIONS
Official Title
Different Immunosuppressive Treatment in iMN
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with idiopathic membranous nephropathy
- Female participants must be post-menopausal, sterile, or using effective contraception
- Off steroids or mycophenolate mofetil for more than 1 month and off alkylating agents or rituximab for over 6 months
- On angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for at least 3 months with controlled blood pressure, or intolerant to ACEI/ARB
- Proteinuria of 4 grams or more per 24 hours and a decrease of 50% or less from baseline
You will not qualify if you...
- Active infection or a secondary cause of membranous nephropathy
- Proteinuria linked to diabetic nephropathy
- Pregnant or breastfeeding
- History of resistance to rituximab, alkylating agents, or corticosteroids
- Patients who relapsed after remission off rituximab or alkylating agents within 6 months are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
S
Sanxi Ai
CONTACT
Y
Yan Qin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here